Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Justus Simon Israel - , Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Laura Maria Marcelin - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Urologie (Autor:in)
  • Christian Thomas - , Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Eva Szczyrbová - , University Hospital Olomouc (Autor:in)
  • Susanne Fuessel - , Klinik und Poliklinik für Urologie, Deutsches Konsortium für Translationale Krebsforschung (Partner: DKTK, DKFZ), Universitätsklinikum Carl Gustav Carus Dresden, Deutsches Krebsforschungszentrum (DKFZ) (Autor:in)
  • Martin Puhr - , Medizinische Universität Innsbruck (Autor:in)
  • Johannes Linxweiler - , Universität des Saarlandes (Autor:in)
  • Shivani Yalala - , University of Helsinki (Autor:in)
  • Wilbert T. Zwart - , Netherlands Cancer Institute (Autor:in)
  • Aria Baniahmad - , Friedrich-Schiller-Universität Jena (Autor:in)
  • Jasper van Goubergen - , Medizinische Universität Innsbruck (Autor:in)
  • Harri M. Itkonen - , University of Helsinki (Autor:in)
  • Adam Sharp - , Institute of Cancer Research (Autor:in)
  • Edward O’Neill - , University of Oxford (Autor:in)
  • Marc Pretze - , Helmholtz-Zentrum Dresden-Rossendorf (Autor:in)
  • Matthias Miederer - , Nationales Centrum für Tumorerkrankungen Dresden, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Holger H.H. Erb - , Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus Dresden, Friedrich-Schiller-Universität Jena (Autor:in)

Abstract

Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus. Therefore, the Department of Urology Dresden hosted an international meeting for scientists and clinical oncologists to discuss the newest advances in AR research. The 2nd International Androgen Receptor Symposium was held in Dresden, Saxony, Germany, from 26–27.04.2024, organised by Dr. Holger H.H. Erb. Following the format of the first meeting, more than 35 scientists from 8 countries attended the event to discuss recent developments, research challenges, and identification of venues in AR research. An important new feature was the involvement of PhD students and young investigators, acknowledging the high scientific quality of their work. The symposium included three covers: new advances from clinical research, basic and translational research, and novel strategies to target AR. Moreover, based on its increasing clinical relevance, a PSMA theranostic mini-symposium was added at the end of the AR symposium to allow the audience to discuss the newest advances in PSMA theranostic. This report focuses on the highlights and discussions of the meeting.

Details

OriginalspracheEnglisch
Aufsatznummer194
FachzeitschriftJournal of Experimental and Clinical Cancer Research
Jahrgang43
Ausgabenummer1
PublikationsstatusVeröffentlicht - Dez. 2024
Peer-Review-StatusJa

Externe IDs

PubMed 39014480
ORCID /0000-0002-6432-5694/work/166324977

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete

Schlagwörter

  • Androgen deprivation therapy, AR, NR3C4, PCa, PSMA